MedPath

Tsunami DRG High Frequency Stimulation Study

Not Applicable
Active, not recruiting
Conditions
Chronic Back Pain
Chronic Back and Leg Pain
Interventions
Device: Spinal Cord Stimulator HF
Device: Spinal Cord Stimulator Sham
Registration Number
NCT03312010
Lead Sponsor
Curonix LLC
Brief Summary

Prospective, double blinded, randomized, clinical study investigating the effects of high frequency SCS over exiting nerve roots at T9 for the treatment of chronic back or back and leg pain.

Detailed Description

All subjects will have two permanent stimulators placed over the exiting nerve roots at T9 at the implant visit. The stimulators can easily be removed for non-responders. High frequency stimulation is typically programmed below sensory threshold. This type of stimulation lends itself to a placebo-controlled trial. For this study subjects will be randomized 1:1 at enrollment into a high frequency or sham group. Neither the subjects nor experimenters will be made aware of their randomization assignment for at least the first month of the trial. Subjects belonging to both groups will be unblinded to their assignment at the 1-month or a later visit (including unscheduled visit) if they have a VAS \> 30 mms. Subjects belonging to the sham group will be reprogrammed with HF stimulation at this point. Subjects belonging to the HF stimulation group will keep stimulating with HF. Subjects reporting a VAS \< 30 mms will continue to be blinded.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
38
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High FrequencySpinal Cord Stimulator HFSubjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
ShamSpinal Cord Stimulator ShamSubjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
Primary Outcome Measures
NameTimeMethod
Responder rate1 month post-implant

a \> 50% reduction in back pain as measured by VAS with the Freedom SCS system in the HF (test) group as opposed to sham and conventional medical management

Secondary Outcome Measures
NameTimeMethod
VAS leg pain1, 3, 6, 9, 12 and 36 months

Percentage change from baseline in VAS for leg pain

VAS back pain1, 3, 6, 9, 12 and 36 months

Percentage change from baseline in VAS for back pain

ODI1, 3, 6, 9, 12 and 36 months

Change from baseline in functionality using the ODI score

Trial Locations

Locations (2)

GZA Sint-Augustinus

🇧🇪

Wilrijk, Antwerpen, Belgium

AZ Delta

🇧🇪

Roeselare, Belgium

© Copyright 2025. All Rights Reserved by MedPath